BIOSAFETY IN THE PHARMACEUTICAL INDUSTRY IN CAMEROON A HOLISTIC-LEGAL APPROACH
Keywords:
Biosafety, pharmaceutical, holisticAbstract
This paper examines the extent at which the laws in the pharmaceutical industry addresses biosafety concerns in Cameroon. Of the findings of this study, it was discovered that the government of Cameroon has put in place regulatory frameworks to help address biosafety concerns in the pharmaceutical industry. The efforts of the government however still remain inadequate to tackle the continuous production and marketing of substandard pharmaceutical products. Helping in finding a solution to the problems, it is recommended that the regulatory authority and medicines registration processes be strengthened.
References
Section 5 (6) of Law No. 2003/006 of 21st April, 2003 to lay down Safety Regulations governing
Biotechnology in Cameroon.
The preamble of the Cartagena Protocol on Biosafety to the Convention on Biological Diversity.
MBOPI., K., (2015), “The Laboratory Biosafety and Biosecurity Guidance in Cameroon”, P. 3.
Kwesi, E., (2011), “Assessment of the Pharmaceutical Management System in Cameroon”, PP.1-
Edward, D., et al, (2007), Principles and Practice of Pharmaceutical Medicines, 2
nd Ed., Wiley,
West Sussex, P.10.
Section 15(1) of Law No. 90/035 of 10th August 1990 on the Exercise of the Profession of
Pharmacists in Cameroon; Section 2(3) of Decree No.98/405/PM of 22nd October 1998 to lay
down Conditions for Approving and Marketing Pharmaceutical Products.
Section 2 (1) of Law No. 90-036 of 10th August ,1990 relating to the Organization and Practice of
Medicine
Ibid, Section 2 (2).
Ibid, Section 4.
Ibid, Section 13.
Ibid, Section 17.
Section 1(1) of Law N° 2003/006 of 21 April 2003 to lay down Safety Regulations governing
Modern Biotechnology in Cameroon.
Ibid, Section 4.
Section 26 of the Decree No 2007/0737/PM of 31ST May 2007 on Modern Biotechnology in
Cameroon.
Section 30 of Decree No.98/405/PM of 22nd October 1998 lays down Conditions for Approving
and Marketing Pharmaceutical Products
htpps:// www.osidimbea.cm/enterprises/a-capitaux-publics/cename/ (Lastly Accessed on August
, 2022).
Kwesi, E., (2011), Op. Cit, n4, P.6.
htpps://www.cename.org/index.php/fr/ (Lastly Accessed on August 4, 2022).
Indian Journal of Health & Medical Law
Volume 5, Issue 1
© Law Journals 2022. All Rights Reserved 34
Article 2 of Decree No. 2018/764 of December 11, 2018 on the Reorganization of the National
Drug Quality Control and Expertise Laboratory.
Ibid, Article 4.
Ibid Article 5.
Ibid Article 3.
https://dpml.cm/index.php/en/presentation/our-missions (Lastly Accessed on August 4, 2022).
Galega, S., et al, (2018), The Law on Pharmaceutical Product Liability in Context, 1st Ed.,
University Printery, Ibadan PP.66-67.
Galega, S., et al, (2018), Op. Cit, n.24, P.79.
Article 6 of the Law no 96/11/of 5th August 1996 on standardization.
MINFI: On an information and sensitization meeting with stakeholders: Cameroon Tribune of
nd February 2011.
Section 5 (43) of Law N° 2003/006 of 21 April 2003 to lay down Safety Regulations governing
Modern Biotechnology in Cameroon.
Ibid, Section 18 (1).
Ibid, Section 19(1)
Ibid, Section.
Ibid.
Section 5(44) of Law N° 2003/006 of 21 April 2003 to lay down Safety Regulations governing
Modern Biotechnology in Cameroon
Section 9 (e) of Law No. 96/12 /05 August 1996 Relating to Environmental Management in
Cameroon.
Ibid, Section 4(1).
Ibid, Section 4(2).
Ibid, Section 5(1) (a-d).
Annex I to Decree No.98/405/PM of 22nd October 1998 lays down Conditions for Approving and
Marketing Pharmaceutical Products